1. E. Arias United States Life Tables 2006. National Vital Statistics Report Volume 58 (28 June 2010). http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_21.pdf.
2. Data available at www.fda.gov/downloads/AboutFDA/Transparency/Basics/UCM247465.pdf.
3. Portfolio analysis and R&D decision making
4. F. M. Scherer Markets and Uncertainty in Pharmaceutical Development Working Paper RWP07-039 Harvard University September 2007. http://web.hks.harvard.edu/publications/getFile.aspx?Id=267.
5. Aranesp (darbepoetin alpha Amgen) Neulasta (pegfilgrastim Amgen) Zocor (simvastatin Merck & Co) Eloxatin (oxaliplatin Sanofi) PegIntron (peginterferon alpha-2b Merck & Co) Humalog (recombinant insulin lispro Eli Lilly) Augmentin (amoxicillin + clavulanate potassium GlaxoSmithKline).